PT1471892E - Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma - Google Patents

Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma Download PDF

Info

Publication number
PT1471892E
PT1471892E PT02740569T PT02740569T PT1471892E PT 1471892 E PT1471892 E PT 1471892E PT 02740569 T PT02740569 T PT 02740569T PT 02740569 T PT02740569 T PT 02740569T PT 1471892 E PT1471892 E PT 1471892E
Authority
PT
Portugal
Prior art keywords
rotigotine
parkinson
therapeutic system
transdermal therapeutic
plasma levels
Prior art date
Application number
PT02740569T
Other languages
English (en)
Inventor
Hans-Michael Wolff
Thomas Lauterbach
Dietrich Wilhelm Schacht
Walter Mueller
Original Assignee
Lohmann Therapie Syst Lts
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1471892(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts, Sanol Arznei Schwarz Gmbh filed Critical Lohmann Therapie Syst Lts
Publication of PT1471892E publication Critical patent/PT1471892E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Elements Other Than Lenses (AREA)
  • Radiation-Therapy Devices (AREA)
  • Steroid Compounds (AREA)
PT02740569T 2001-05-08 2002-05-06 Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma PT1471892E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111109A EP1256339B1 (en) 2001-05-08 2001-05-08 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine

Publications (1)

Publication Number Publication Date
PT1471892E true PT1471892E (pt) 2009-12-23

Family

ID=8177356

Family Applications (2)

Application Number Title Priority Date Filing Date
PT01111109T PT1256339E (pt) 2001-05-08 2001-05-08 Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
PT02740569T PT1471892E (pt) 2001-05-08 2002-05-06 Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT01111109T PT1256339E (pt) 2001-05-08 2001-05-08 Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina

Country Status (15)

Country Link
EP (3) EP1344522A1 (pt)
JP (2) JP5026656B2 (pt)
KR (1) KR100974974B1 (pt)
CN (2) CN1606435A (pt)
AT (2) ATE251901T1 (pt)
CY (1) CY1109861T1 (pt)
DE (2) DE60100994T2 (pt)
DK (2) DK1256339T3 (pt)
ES (2) ES2204780T3 (pt)
HK (1) HK1049444B (pt)
HU (1) HU229350B1 (pt)
PT (2) PT1256339E (pt)
RU (1) RU2272625C2 (pt)
WO (1) WO2002089778A2 (pt)
ZA (1) ZA200209982B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1796610A4 (en) * 2004-09-29 2012-12-05 Schwarz Pharma Inc TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON DISEASE
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2490673A2 (en) * 2009-10-19 2012-08-29 Actavis Group Ptc Ehf Amorphous rotigotine co-precipitates
AU2010334805B2 (en) 2009-12-22 2015-01-22 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
DE102014114282A1 (de) 2014-10-01 2016-04-07 Neuraxpharm Arzneimittel Gmbh Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson
CN110121344A (zh) 2016-12-28 2019-08-13 久光制药株式会社 含布托啡诺的贴附剂
DE102018120505A1 (de) 2017-10-20 2019-04-25 Amw Gmbh Verhinderung der Kristallisation von Wirkstoffen in transdermalen Darreichungssystemen
EP3854388B1 (de) 2020-01-24 2023-10-04 Luye Pharma Switzerland AG Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751515B2 (ja) * 1986-09-10 1995-06-05 明治製菓株式会社 経皮吸収製剤
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten

Also Published As

Publication number Publication date
ATE251901T1 (de) 2003-11-15
EP1471892A2 (en) 2004-11-03
EP1344522A1 (en) 2003-09-17
DK1471892T3 (da) 2009-12-07
ZA200209982B (en) 2003-03-24
EP1471892B1 (en) 2009-09-30
EP1256339A1 (en) 2002-11-13
JP5026656B2 (ja) 2012-09-12
EP1256339B1 (en) 2003-10-15
RU2003133217A (ru) 2005-04-20
HK1049444A1 (en) 2003-05-16
JP2004536054A (ja) 2004-12-02
CN102172351A (zh) 2011-09-07
HUP0500525A2 (hu) 2005-09-28
CN1606435A (zh) 2005-04-13
DK1256339T3 (da) 2004-02-09
WO2002089778A3 (en) 2004-08-19
CY1109861T1 (el) 2014-09-10
ES2204780T3 (es) 2004-05-01
WO2002089778A2 (en) 2002-11-14
DE60233898D1 (de) 2009-11-12
DE60100994T2 (de) 2004-07-22
CN102172351B (zh) 2013-07-17
DE60100994D1 (de) 2003-11-20
PT1256339E (pt) 2004-02-27
KR100974974B1 (ko) 2010-08-09
ATE444061T1 (de) 2009-10-15
ES2331787T3 (es) 2010-01-15
HK1049444B (zh) 2004-03-19
JP2010106037A (ja) 2010-05-13
KR20030016373A (ko) 2003-02-26
HU229350B1 (en) 2013-11-28
RU2272625C2 (ru) 2006-03-27

Similar Documents

Publication Publication Date Title
PT1471892E (pt) Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
MXPA02012793A (es) Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
CA2385755A1 (en) Prevention of colorectal cancer
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
MXPA05012826A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen.
WO2006039532A3 (en) Transdermal therapeutic system for parkinson’s disease
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
TR200301916T4 (tr) Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem.
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?